Funding Round attributes
General Proximity, a San Francisco-based biotechnology platform company, has successfully secured $16 million in funding to advance its innovative therapeutic solutions targeting traditionally undruggable proteins associated with critical health conditions such as cancer, cardiometabolic diseases, neurodegeneration, and longevity. The funding round was led by Aydin Senkut at Felicis, with participation from notable investors including Y Combinator, age1, Modi Ventures, and Wilson Sonsini. Additionally, prominent angel investors such as Jeff Dean (Head of Google AI), Uri Lopatin (Khosla, YC, Pardes), Ben Mann (Co-Author GPT-3, Co-Founder Anthropic), Alec Nielsen (CEO Asimov), Trevor Martin (CEO Mammoth), Juan Benet (Founder Filecoin), Nish Bhat (Co-Founder Color Health), Jim Dahl (Rock Creek Capital), and De Thompson V (Legends Capital) contributed to this round. Under the leadership of Founder and CEO Armand B. Cognetta III, PhD, General Proximity has developed the proprietary OmniTAC platform. This platform enables precise and selective modification of disease-driving proteins, creating therapeutic opportunities for targets that have traditionally been considered undruggable. The company's initial drug candidates are focused on oncology, cardiometabolic diseases, neurodegenerative diseases, and longevity, addressing areas with significant unmet medical needs. To support its mission, General Proximity has assembled a Scientific & Strategic Advisory Board comprising key opinion leaders from top biotechnology and pharmaceutical companies. Notable members include Martin Babler (Genentech, Principia, Alumis), Lawrence Hamann (Bristol-Myers Squibb, Novartis, Celgene, Takeda, Interdict), and Andy Crew (Astellas, Arvinas, Siduma), alongside academic experts in cancer biology and neurodegeneration. The $16 million in funding is earmarked to accelerate the development of treatments targeting proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity. This investment reflects a strong vote of confidence in General Proximity's approach to addressing some of the most challenging targets in medicine. General Proximity's emergence from stealth mode marks a significant milestone in the biotech industry, as it seeks to pioneer the next generation of induced proximity medicines. By leveraging its OmniTAC platform, the company aims to provide precise control over protein interactions, offering new therapeutic avenues for diseases that have been difficult to treat with existing modalities. GENERAL PROXIMITYThe company's focus on undruggable targets positions it at the forefront of drug discovery, with the potential to make a substantial impact on global health by addressing diseases with high unmet needs. The strategic assembly of its advisory board and the backing of prominent investors underscore the industry's recognition of General Proximity's innovative approach and its potential to transform therapeutic development. .As General Proximity advances its pipeline, the biotech community and healthcare stakeholders will be closely monitoring its progress in bringing these novel therapies to market, with the hope of offering new treatment options for patients worldwide.
